Project Grant R01DE033759
- This $648,881 Project Grant award from the U.S. Department of Agriculture's National Institute of Food and Agriculture (NIFA) under the Agriculture and Food Research Initiative (AFRI) program supports the development of a mucosal vaccine to prevent influenza virus infections in cows and reduce transmission between animals and humans. The goal is to create a nasal spray vaccine that can trigger long-lasting mucosal immunity in the respiratory system, which is more effective at preventing...
- This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $434,170 to the University of Texas Health Science Center at Houston (UTHealth) to develop engineered bacterial in situ vaccines against oral cancer. The key products and services to be delivered under this grant include: 1) developing non-pathogenic E. coli bacteria that can be programmed to secrete the...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $314,363 to Via Therapeutics, LLC, a for-profit limited liability company based in Austin, Texas, to develop a microneedle-based mRNA flu vaccine candidate for transcutaneous immunization. The goal is to create a stable, multivalent mRNA flu vaccine that can be administered intradermally using proprietary thin-film...
- This $423,500 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, supports the development of a novel mucosal cytotoxic T-lymphocyte (CTL)-based HIV vaccine. The research aims to design an HIV vaccine capable of exclusively inducing HIV-specific CD8+ CTLs without eliciting HIV-specific CD4+ T cells, in order to provide protection against HIV infection through mucosal routes. The...
- This $261,846 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) is supporting the development of an intranasal protein subunit vaccine against Pseudomonas aeruginosa (PA) using the Tobacco Mosaic Virus (TMV) as a delivery platform. PA is a critical public health threat due to the spread of antimicrobial resistance, and new prevention approaches are needed. The vaccine is being developed by the New York...
- This $437,477 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to develop a human lymph node-on-a-chip microphysiological system for evaluating the effectiveness of vaccines against infectious diseases. The project, to be conducted by New York University (NYU) over a period from June 2025 to May 2027, seeks to address the lack of reliable preclinical models that can accurately replicate human adaptive...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $404,539 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Rochester General Hospital. The grant will fund the development and evaluation of a novel Haemophilus influenzae lipoprotein fusion vaccine and vaccine platform. Key research objectives include assessing the immunogenicity and protective efficacy of lipidated and fusion protein constructs against nasopharyngeal...
- This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), provides $571,410 to Pharynvac Surgical Technology Inc. to develop a novel device called "Pharynvac" that can mitigate key issues in sinonasal surgeries. Specifically, the Pharynvac device aims to reduce surgical staff exposure to pathogens and toxins, prevent...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $929,500 to the Icahn School of Medicine at Mount Sinai to investigate the mechanisms of action for mRNA-based and Newcastle Disease Virus (NDV)-based COVID-19 vaccine platforms in inducing mucosal immune responses. The researchers aim to understand how these vaccine platforms can elicit long-lasting protective systemic and mucosal immunity...
- This STTR Phase I project by Immuno Nano Med, Inc. was awarded a $305,000 grant from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program. The project aims to demonstrate the feasibility of producing a novel room-temperature-stable, dry-powder inhalable influenza vaccine, replacing current needle-based flu shots that require refrigerated storage. This innovative vaccine technology has the potential to significantly lower storage costs, improve...
FLOSS: A NOVEL METHOD FOR ORAL MUCOSAL VACCINATION - FLOSS: A NOVEL METHOD FOR ORAL MUCOSAL VACCINATION THE OVERALL GOAL OF THIS PROPOSAL IS TO DEVELOP A NOVEL METHOD OF ORAL CAVITY MUCOSAL VACCINATION. THE MUCOSAL SURFACES SERVE AS PORTALS OF ENTRY FOR A VAST MAJORITY OF PATHOGENS SUCH AS INFLUENZA VIRUS AND HIV. IT IS RECOGNIZED THAT A STRONG IMMUNE RESPONSE AT BOTH THE MUCOSAL AND SYSTEMIC COMPARTMENTS IS MORE EFFECTIVE AT COMBATING THESE INFECTIONS THAN AN IMMUNE RESPONSE IN JUST THE SYSTEMIC COMPARTMENT. HOWEVER, PARENTERAL INJECTIONS DO NOT STIMULATE STRONG MUCOSAL IMMUNITY. TO ACHIEVE THIS, VACCINES MUST BE DELIVERED THROUGH THE MUCOSAL SURFACES. FURTHERMORE, MUCOSAL VACCINATIONS CAN BE PAINLESS AND BETTER ACCEPTED (OF COURSE DEPENDS ON THE ROUTE) AS COMPARED TO PAINFUL SHOTS. THE ORAL CAVITY IS AN EXTREMELY ATTRACTIVE ROUTE FOR DELIVERING VACCINES DUE TO IT'S EASE OF ACCESSIBILITY AND THE RELATIVELY MILD ENVIRONMENT COMPARED TO THE STOMACH. WITHIN THE ORAL CAVITY, THE BUCCAL AND SUBLINGUAL MUCOSA HAVE BEEN EXTENSIVELY RESEARCHED, HOWEVER, POOR PERMEABILITY OF VACCINES THROUGH THESE MUCOSAL TISSUES HAS MADE IT DIFFICULT TO TRANSLATE THESE ROUTES TO THE CLINIC. NONETHELESS, RESEARCH HAS SHOWN THAT IF VACCINES ARE DELIVERED THROUGH THE ORAL CAVITY, IMMUNE RESPONSES CAN BE STIMULATED IN THE DISTANT VAGINAL, RESPIRATORY, AND INTESTINAL MUCOSA, OFFERING PROTECTION AT ALL THESE OTHER SITES. IN OTHER WORDS, THE ORAL CAVITY HAS POTENTIAL TO BE USED FOR VACCINATION AGAINST A BROAD RANGE OF PATHOGENS SUCH AS INFLUENZA AND HIV. THEREFORE, A BREAKTHROUGH IN SUCCESSFUL DELIVERY OF VACCINES THROUGH THE ORAL CAVITY COULD HAVE A PARADIGM-SHIFTING IMPACT ON VACCINATIONS. HERE WE PROPOSE THAT A FLOSS CAN BE USED TO TARGET THE JUNCTIONAL EPITHELIUM FOR VACCINATION. THE JUNCTIONAL EPITHELIUM IS A UNIQUE EPITHELIAL TISSUE THAT HAS EXCEPTIONALLY HIGH PERMEABILITY AND PROVIDES A DOORWAY INTO THE MUCOSA. HOWEVER, BECAUSE IT IS LOCATED AT THE BASE OF THE GUM POCKET IT IS HARDER TO TARGET. WE POSTULATE THAT THE FLOSS, A COMMON DENTAL DEVICE USED BY MILLIONS, COULD BE COATED WITH A VACCINE AND USED FOR VACCINATION. OUR HYPOTHESIS IS THAT FLOSS-BASED VACCINATION THROUGH THE JUNCTIONAL EPITHELIUM CAN STIMULATE SYSTEMIC AND MUCOSAL HUMORAL AND CELLULAR IMMUNE RESPONSES AGAINST DIFFERENT ANTIGENS. THIS HYPOTHESIS IS BACKED BY OUR STRONG PRELIMINARY DATA. THE OBJECTIVE OF THIS RESEARCH PROPOSAL IS TO BUILD ON THIS PRELIMINARY DATA AND DEVELOP THIS NOVEL METHOD OF VACCINATION INTO A RELIABLE AND REPRODUCIBLE METHOD OF VACCINATION. THE AIMS ARE: I) COMPREHENSIVE CHARACTERIZATION OF IMMUNE RESPONSE GENERATED THROUGH JUNCTIONAL EPITHELIUM IMMUNIZATION IN MICE, II) CHARACTERIZATION OF THE NATURE OF IMMUNE STIMULATION FOLLOWING JUNCTIONAL EPITHELIUM VACCINATION IN MICE, AND III) CHARACTERIZATION OF SYSTEMIC AND MUCOSAL IMMUNITY FROM FLOSS-BASED VACCINATION IN PIGS. THIS NEW APPROACH OF VACCINATION WILL BE ASSESSED IN MICE AND PIGS, WHICH INCREASES THE TRANSLATIONAL POTENTIAL OF THIS WORK. BECAUSE THE FLOSS IS NEEDLE FREE, IT IS PAINLESS AND COULD BE SELF-APPLIED. IT ALSO HAS POTENTIAL TO BE DISTRIBUTED THROUGH POSTAL MAIL, WHICH COULD MAKE VACCINATION CAMPAIGNS EASIER. OVERALL, THIS RESEARCH PROPOSES TO ESTABLISH A NEW PARADIGM IN ORAL MUCOSAL VACCINATION, WHICH HAS POTENTIAL FOR SIGNIFICANT IMPACT ON PUBLIC HEALTH.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $568.6k | 6/11/25 | ||
| Not listed | $601.4k | 7/26/24 | ||
| Not listed | $601.4k | 7/26/24 |